VasoLead

VasoLead is a private Israeli healthcare company developing locally applied small-molecule therapeutics for sexual health disorders. Publicly identifiable activity centers on VL#FIA3-30, a topical dual-active vasodilator formulation for erectile dysfunction that was listed in a Phase 1/Phase 2 clinical study. Patent disclosures indicate the company has explored combinations of known vasoactive agents in topical carriers for erectile dysfunction and potentially female sexual arousal disorder. The company appears to be small, privately held, and focused on reformulating established vasodilatory agents into localized treatments rather than building a broad multi-asset pipeline. Its visible footprint is limited, suggesting a niche development-stage business rather than a commercial-stage biopharma company.